On November 10, 2024, the kick-off meeting of the Phase I/II clinical trial of the recombinant respiratory syncytial virus (RSV) vaccine (CHO cell) independently developed by Maxvax was held in China’s Henan Province, and the enrollment of the first subjects was completed on the same day, marking the official start of the clinical trial of this vaccine candidate.

Pre-clinical studies have shown that this product has a strong safety and immunogenicity profile and has shown good protection effect in animal attack model. It adopts the novel MA103 adjuvant system, which can significantly enhance the level of humoral immune response and inducing potent cell-mediated immune responses. The Phase I/II clinical trials will validate the safety and immunogenicity at different doses in people aged 18 years and above and people aged 50 years and above, providing supportive data for the selection of dose for the Phase III clinical trial.

Maxvax’s RSV candidate is the first domestically developed RSV vaccine with recombinant protein technology approved for clinical trials by China’s Center for Drug Evaluation (CDE). It helps prevent lower respiratory tract diseases caused by respiratory syncytial viruses and reduce morbidity and mortality. For years, the respiratory syncytial virus has been a challenge to global public heath, but currently there is no in-country developed RSV vaccine on the market. Maxvax’s RSV candidate is expected to fill the gap in the domestic market and meet the needs of public health development.